Mallinckrodt plc Ordinary Share (NYSE:MNK):
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in Pennsylvania.
The company is now down since yesterday’s close of $63.04.
Shares of the company are trading at $61.38 which is marginally under $69.45, the 50 day moving average and which is just a bit below the 200 day moving average of $66.80. The 50 day moving average went down $-8.07 or -11.62% and the 200 day average went down $-5.42 or -8.12%.
The company currently has a P/E ratio of 11.57 and market cap is 6.61B. In the latest earnings report the EPS was $5.30 and is estimated to be $7.64 for the current year with 107,713,000 shares currently outstanding. Next quarter’s EPS is forecasted at $1.90 with next year’s EPS projected to be $8.09.
A few brokerage analysts have provided guidance on the company. August 31 investment analysts at Deutsche Bank left the stock rating at “Buy” but lowered the price target to $84.00 from $87.00. On August 25 Barclays held the company rating at “Overweight” and raised the price target from $80.00 to $112.00.
On August 24 Piper Jaffray left the company rating at “Overweight” and moved up the price target to $112.00 from $102.00. On August 12, 2016 Stifel Nicolaus starting coverage on MNK with a rating of “Buy”.
Equity analyst BMO Capital initiated coverage on MNK setting a rating of “Outperform”. May 4 investment analysts at JP Morgan made no change to the company rating of “Neutral” but moved down the price target to $85.00 from $120.00.